Based on a statistic that was recently released by the National Cancer Institute, nearly forty percent of all people will be diagnosed with a form of cancer before they die. This fact, while quite alarming to most, is one of the main motivators for Dr. Clay Siegall, co-founder, and CEO of Seattle Genetics. While Dr. Clay Siegall has received numerous accolades during his career, it is his latest endeavor that is making waves throughout the biotechnology industry. By championing research that is geared at the development of therapeutic drugs, Dr. Siegall and his staff at Seattle Genetics, have tackled the treatment of drugs with high mortality rates head on. What separates Dr. Siegall from his counterparts, is his willingness to utilize cutting edge scientific techniques in an effort to eradicate existing diseases. The newly developed antibody drug conjugates, based on initial testing, is set to change the way that we treat and live with cancer. What separates antibody drug conjugates from the myriad of other cancer treatments available today, is their ability to target specific types of cancer, treating them efficiently and effectively. Affecting nearly 70,000 people each year, Hodgkin’s lymphoma is one of the common and devastating forms of cancer that we see. The good news is that the antibody drug conjugates being developed by Dr. Siegall and his staff at Seattle Genetics, have had a high success rate in treating Hodgkin’s lymphoma as well as a number of other forms of cancer. Dr. Siegall recently began collaborating with Takeda Pharmaceutical Company Limited for the development of ADCetris, which has had significant success in treating Hodgkin’s lymphoma and is now available in 66 countries around the globe.
Co-founder and Chief Executive Officer of Seattle Genetics, Dr. Clay Siegall, has nearly twenty years of experience in the field of oncology biotechnology. Dr. Siegall began working for Bristol-Meyers Squibb Pharmaceutical Research Institute in 1991 as the Senior Research Investigator, up until he co-founded Seattle Genetics in 1997. Dr. Clay is currently a member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation and he has received the Pierce Award.